Positive trial results announced for TTHX1114 in patients with fuchs endothelial corneal dystrophy
Trefoil Therapeutics recently announced positive Phase 2 results for TTHX1114, an engineered fibroblast growth factor-1 (FGF1) variant, in patients with fuchs endothelial corneal dystrophy (FECD). TTHX1114 is delivered as an intracameral injection into the anterior chamber of the eye of patients undergoing a Descemet Stripping Only (DSO) procedure.
After a single intracameral injection of TTHX1114 in the Phase 2 STORM trial, vision was restored to 20/40 in a mean time of 4.2 weeks following DSO and was well tolerated, with no serious adverse events reported.
A significant dose-dependent effect of TTHX1114 on the recovery of central corneal thickness, with median central corneal thickness recovered to better than baseline by day 84, was also reported.
“The STORM trial data show endothelial cell restoration and patient-reported visual recovery that indicate endothelial cells are regenerating, migrating, and helping to accelerate healing after DSO and a single injection of TTHX1114,” said Francis W. Price, Jr, MD, founder and president of Price Vision Group and the Cornea Research Foundation of America, and the lead investigator in the trial in a press release. “For the millions of people with corneal endothelial disease, this has the potential to be a first-line pharmacological treatment option.”
Read the full press release here.